A Single-center Phase 2 Study of Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer
Latest Information Update: 07 Feb 2024
At a glance
- Drugs Carboplatin (Primary) ; Paclitaxel (Primary) ; Sintilimab (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms Neo-Pre-IC
Most Recent Events
- 18 Oct 2023 Status changed from recruiting to active, no longer recruiting.
- 06 Jun 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2027.
- 06 Jun 2023 Planned primary completion date changed from 1 Dec 2021 to 1 Sep 2024.